Covid-19 adult MDV vaccine

Ended Definitive Contract Awarded Last action

Contract number
W58P0522C0016
Awardee
Awarding agency
Obligated
$4,038,717,532

Award facts

Opportunity
  • W58P0522R0006 Solicitation number
Contract value 47% obligated
  • $4,039,016,223.50 Current, with exercised options
  • $8,660,000,000.00 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
Set-aside
No set-aside
Competition
Not Competed · 1 offer Only One Source
Pricing
Firm Fixed Price
Place of performance
New York, NY 10017, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00006 · Covid-19 action: the purpose of this modification is to process the final DE-obligation and right size the contract total value to reflect $8.66B. -$1,532,318
Exercise an Option P00005 · Covid-19 action the purpose of this modification is to exercise clin 0006 in support of OCONUS shipping, RE-define the term "delivery" and extend clin 0002… $250,000
Funding Only Action P00004 · Covid-19 action the purpose of this modification is to realign pediatric and SDV vaccine doses and dcma doddac administrative correction. -$150
Other Administrative Action P00003 · Transfer of contract and unexercised clins to HHS $0
Exercise an Option P00002 · The purpose of this modification is to exercise options 1,2 and 3 for covid-19 adult MDV vaccine, as well as obligating funding. $840,000,000
Supplemental Agreement for work within scope P00001 · Change to delivery schedule for adult multidose vials. $0
Original award $3,200,000,000

About this award

Written by GovTribe AI ·

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense (DOD - Army - USASC) awarded an $8.66 billion definitive contract to Pfizer Inc., doing business as Pfizer, for COVID-19 Adult MDV Vaccine. The contract is a firm fixed price agreement with a place of performance in New York, NY. The period of performance spans from June 29, 2022 through February 29, 2024. No subcontractors were identified.

Quick answers

Who was awarded contract W58P0522C0016?

W58P0522C0016 was awarded to Pfizer Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on June 29, 2022.

How much is contract W58P0522C0016 worth?

The government has obligated $4,038,717,532 on W58P0522C0016. Its current value, with exercised options, is $4,039,016,224. Its potential value, with all options, is $8,660,000,000.

Which agency awarded contract W58P0522C0016?

ACC Aberdeen Proving Ground (Army Contracting Command) awarded W58P0522C0016, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

Was contract W58P0522C0016 competed?

The extent of competition for W58P0522C0016 was not competed. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login